Navigation Links
Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
Date:3/18/2008

osciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase trials in solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initiation of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forw
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
2. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
3. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
4. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
5. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
6. Kosan Announces February 28, 2008 Conference Call and Webcast
7. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
8. Kosan Announces Third Quarter 2007 Financial Results
9. Kosan to Reacquire Epothilone Program From Roche
10. Kosan Biosciences to Host Research & Development Day on October 31, 2007
11. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study ... the study of the structure and functions of proteomes ... bioinformatics tools and technology. Genomics involves the mapping of ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... forecasts of its potential revenue from new rodenticide research ... investors and analysts on July 22, 2014, Neogen,s CEO ... regarding this research. "It was my intent ... the potential of a new type of rodenticide, but ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... Santini, Jr., PhD, CEO of,MicroCHIPS, Inc., is named ... the,2008 class of "young geniuses shaping the future ... Dr. Santini is the only honoree who is ... commercial venture.,His company, MicroCHIPS, is pioneering intelligent medical ...
... Joins as Associate Director, SAN FRANCISCO, ... today announced that it has launched Invigorate,Communications, ... serving,the diverse communications needs of leading biopharmaceutical, ... interested in,building health-based brands. Invigorate currently provides ...
... 14 Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: ... systems, announced today that its,distributor, Laszlo Meszaros of ... Mammography (CTLM(R)) system for Budapest, Hungary., (Logo: ... will be installed at the new MeDoc HealthCare ...
Cached Biology Technology:MicroCHIPS CEO Named in Popular Science's 'Seventh Annual Brilliant 10' 2WeissComm Launches Invigorate Communications to Help Companies Build Successful Health-Based Brands 2Imaging Diagnostic Systems Sells Its CT Laser Mammography System to Budapest, Hungary 2
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
(Date:7/24/2014)... of the primordial soup in which life arose have been ... University of East Anglia. , Research published today in the ... plants, yeast and very likely also in animals still perform ... of life some four billion years ago. , The ... or ocean as a result of the combination of metals, ...
(Date:7/24/2014)... a new drug that successfully treated lupus in mice, a ... $250,000 grant to expand his research to a new version ... range of autoimmune diseases., Chandra Mohan, Hugh Roy and Lillie ... published a study in Arthritis Research & Therapy outlining the ... mice and reduced the number of cases of lupus-related kidney ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... A deep ocean current with a volume equivalent to 40 ... near the Kerguelen plateau, in the Indian Ocean sector of ... paper published today in Nature Geoscience , the researchers ... surface as an important pathway in a global network ...
... National Oceanography Centre in Southampton, have today set sail from ... Ocean affected by ash from the Icelandic volcano eruption to ... of the ocean the productivity of microscopic plants, called phytoplankton, ... sequester carbon dioxide from the atmosphere, is limited by the ...
... Spanish . , Two new compact oakleaf ... by Agricultural Research Service (ARS) scientists. "Ruby Slippers" ... geneticist Sandy Reed with the U.S. National Arboretum,s Floral ... The arboretum is operated by ARS, the principal intramural ...
Cached Biology News:Massive Southern Ocean current discovered 2Scientists to measure impact of volcanic ash on ocean biology 2New hydrangea cultivars for landscape gardens 2